Προωθημένο
Understanding the SCLC Drug Development Pathway: State of the Art and Beyond
  Small Cell Lung Cancer continues to challenge oncologists worldwide as one of the most aggressive and treatment-resistant malignancies. Despite demonstrating initial responsiveness to conventional chemotherapy and radiation protocols, patients inevitably experience disease recurrence, leading to survival rates considerably lower than other lung cancer types. This daunting clinical...
0 Σχόλια 0 Μοιράστηκε 215 Views 0 Προεπισκόπηση
Προωθημένο
Προωθημένο
Προωθημένο